The Biosimilars Conference at the University of Washington
Designed for Professionals in the Pharmaceutical and Biotech Industries
March 19-20, 2010
University of Washington
Thank you to all who attended our March 2010 conference.
The expiration of patents on therapeutic biological products raises major technological and policy questions about potential "generic" equivalents – so-called biosimilar or follow-on biologics. While there may be great opportunities for manufacturers and professionals in the biosimilars field, parallel concerns regarding manufacturing, clinical trials, economics, intellectual property, analytical methods, safety and efficacy arise. The UW Conference on Biosimilars will provide updates and explore potential solutions to these concern.
Respected faculty from the University of Washington and research and business professionals from local biomedical companies will lead you through the state of biosimilars. Participants at the conclusion of the conference will be able to:
- Explain the current availability and impact of biosimilars in Latin America
- Compare and contrast the intellectual property issues between pioneers and generics
- Analyze the FDA's current view of biosimilars
- Explain the economics of biosimilars through case examples.
- Determine issues surrounding biosimiliars and clinical trials.
Who should attend?
The program is designed to serve the needs of professionals in the pharmaceutical and biotech industries who work on clinical development, process development, safety and quality assurance, regulatory compliance, legal affairs and corporate strategic planning. College students who interested in advancing their knowledge about biosimilars are encouraged to attend.
Why should you attend?
- Connect with other professionals in the field
- Acquire pertinent resources
- Prepare for the future of biosimilars in the market